← Back to Search

Neuromodulation

ThorS-MagNT Treatment for Gastroparesis (ThorS-MagNT Trial)

N/A
Waitlist Available
Led By Amol Sharma, MD, MS
Research Sponsored by Augusta University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 weeks
Awards & highlights

ThorS-MagNT Trial Summary

Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study

Eligible Conditions
  • Gastroparesis

ThorS-MagNT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Responder rate
Secondary outcome measures
Gastric emptying time
Patient Global Impression of Improvement (PGI-I)
Sub-scores of the ANMS GSCI-DD

ThorS-MagNT Trial Design

1Treatment groups
Experimental Treatment
Group I: ThorS-MagNT TreatmentExperimental Treatment1 Intervention
Low-frequency, low-intensity repetitive magnetic stimulation bilaterally at T7-8 intravertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.

Find a Location

Who is running the clinical trial?

Augusta UniversityLead Sponsor
211 Previous Clinical Trials
85,056 Total Patients Enrolled
1 Trials studying Gastroparesis
48 Patients Enrolled for Gastroparesis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,359 Previous Clinical Trials
4,314,580 Total Patients Enrolled
19 Trials studying Gastroparesis
3,407 Patients Enrolled for Gastroparesis
Amol Sharma, MD, MSPrincipal InvestigatorAugusta University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study
2020. "Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04706832.
All > Diabetic Gastroparesis > Gastroparesis
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top